CoChat

Deep response in multiple myeloma: a critical review.

Open access
Fulciniti, Mariateresa, Munshi, Nikhil C., Martinez-Lopez, Joaquin · 2015 · BioMed Research International

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

Novel and more effective treatment strategies against multiple myeloma (MM) have significantly prolonged patients’ survival and raised interest in the depth of response and its association with clinical outcome. Minimal residual disease (MRD) has emerged as one of the most relevant prognostic factors in MM and should be included in a new definition of complete response (CR). Although further standardization is still required, MRD monitoring should be applied in prospective clinical trials as a sensitive tool to compare and evaluate the efficacy of different treatment strategies, particularly in the consolidation and maintenance settings, and implement individualized therapy-monitoring approaches. Here, we review current definition of deep response in MM, advantages and limitations of current MRD assessment assays, clinical evidences for MRD monitoring as a prognostic tool for therapeutic decisions in MM, and challenges to develop uniform criteria for MRD monitoring.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2015/832049

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Ludwig H. Slavka G. Hubl W. Usage of HLC-ratio, FLC-ratio, Ife, PBMC infiltration and isotype suppression at best response reveals isotype suppression as most powerful parameter for identification of multiple myeloma patients with long survival ASH Annual Meeting Abstracts 1817 120 21 p. 1817

Cited by

See all 40

Metadata

Authors
Fulciniti, M., Munshi, N. C., & Martinez-Lopez, J.
Affiliations
  • Harvard University (US)
  • Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
Corresponding author
Fulciniti, Mariateresa
Venue
BioMed Research International
Published
2015
Volume
2015
Pages
1-7
ISSN
  • 1110-7243 (ISSN-L)
  • 2314-6133
  • 2314-6141
OpenAlex
W2191437528
Cited by
40
References
54
Citations by year
2026: 1 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 11 · 2020: 6 · 2019: 4 · 2018: 1 · 2017: 10 · 2016: 2
FWCI
0.65
Type
journal article
Language
en
Open access
Locations
  • BioMed Research International (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Keywords
multiple myeloma, minimal residual disease, deep response, complete response, MRD monitoring, prognostic factors, consolidation therapy, maintenance therapy, treatment response criteria
MeSH terms
Humans, Multiple Myeloma, Prognosis, Remission Induction, Treatment Outcome, Neoplasm, Residual

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.